Market Research Logo

Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Pipeline Review, H1 2016

Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Pipeline Review, H1 2016

Summary

Global Markets Direct’s, ‘Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Pipeline Review, H1 2016’, provides in depth analysis on Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) targeted pipeline therapeutics.

The report provides comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR)
  • The report reviews Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Introduction
Global Markets Direct Report Coverage
Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) Overview
Therapeutics Development
Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Products under Development by Stage of Development
Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Products under Development by Therapy Area
Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Products under Development by Indication
Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Pipeline Products Glance
Late Stage Products
Early Stage Products
Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Products under Development by Companies
Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Products under Development by Universities/Institutes
Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Therapeutics Assessment
Assessment by Monotherapy/Combination Products
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Companies Involved in Therapeutics Development
AstraZeneca Plc
Aeterna Zentaris Inc.
Asubio Pharma Co., Ltd.
Asubio Pharma Co., Ltd.
Alize Pharma SAS
Helsinn Healthcare S.A.
Pfizer Inc.
RaQualia Pharma Inc.
Rhythm Pharmaceuticals, Inc.
Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Drug Profiles
anamorelin hydrochloride - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-12861903 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZP-531 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DLN-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
G-51 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-03 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-04 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
macimorelin acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relamorelin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00433412 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Agonize Ghrelin Receptor for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Ghrelin Receptor for Alcoholism - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inverse Agonize Ghrelin Receptor for Obesity - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Dormant Projects
Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Discontinued Products
Growth Hormone Secretagogue Receptor Type 1 (GHS-R or GH-Releasing Peptide Receptor or GHRP or Ghrelin Receptor or GHSR) - Featured News & Press Releases
Apr 04, 2016: Motus Completes Enrollment of Phase 2b Clinical Trial of Relamorelin for Diabetic Gastroparesis
Apr 04, 2016: Motus Presents Clinical Proof-of-Concept Results for Relamorelin in the Treatment of Anorexia
Feb 23, 2016: Helsinn Announces Publication of Anamorelin ROMANA 1 and ROMANA 2 Phase III Studies in The Lancet Oncology
Jan 19, 2016: Aeterna Zentaris Concludes Successful Meeting of Clinical Investigators for Confirmatory Phase 3 Trial of Macrilen
Nov 30, 2015: Helsinn Announces European Medicines Agency Acceptance of Marketing Authorization Application for Anamorelin HCL
Nov 19, 2015: Aeterna Zentaris Announces First Patient Enrolled for Confirmatory Phase 3 Trial of Macrilen for the evaluation of AGHD
Oct 29, 2015: Alize Pharma reports positive safety and efficacy results from a Phase Ib trial of AZP-531 in type 2 diabetes and provides an update on its overall clinical program
Sep 09, 2015: Additional data for anamorelin in ROMANA 1 and ROMANA 2 studies
Jun 25, 2015: Aeterna Zentaris Announces Selection of Ergomed to Conduct Confirmatory Phase 3 Clinical Trial of Macrilen in AGHD
May 26, 2015: Aeterna Zentaris’ Confirmatory Phase 3 Study for Macrilen in AGHD Meets EMA’s Study-Design Expectations
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Number of Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016
Products under Development by Companies, H1 2016 (Contd..1)
Number of Products under Investigation by Universities/Institutes, H1 2016
Products under Investigation by Universities/Institutes, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Stage and Mechanism of Action, H1 2016
Number of Products by Stage and Route of Administration, H1 2016
Number of Products by Stage and Molecule Type, H1 2016
Pipeline by AstraZeneca Plc, H1 2016
Pipeline by Aeterna Zentaris Inc., H1 2016
Pipeline by Asubio Pharma Co., Ltd., H1 2016
Pipeline by Alize Pharma SAS, H1 2016
Pipeline by Helsinn Healthcare S.A., H1 2016
Pipeline by Pfizer Inc., H1 2016
Pipeline by RaQualia Pharma Inc., H1 2016
Pipeline by Rhythm Pharmaceuticals, Inc., H1 2016
Dormant Projects, H1 2016
Dormant Projects (Contd..1), H1 2016
Dormant Projects (Contd..2), H1 2016
Discontinued Products, H1 2016
Discontinued Products (Contd..1), H1 2016
List of Figures
Number of Products under Development for, H1 2016
Number of Products under Development by Therapy Area, H1 2016
Number of Products under Development by Top 10 Indication, H1 2016
Comparative Analysis by Late Stage Development, H1 2016
Comparative Analysis by Early Stage Products, H1 2016
Assessment by Monotherapy/Combination Products, H1 2016
Number of Products by Mechanism of Actions, H1 2016
Number of Products by Stage and Mechanism of Actions, H1 2016
Number of Products by Routes of Administration, H1 2016
Number of Products by Stage and Routes of Administration, H1 2016
Number of Products by Molecule Types, H1 2016
Number of Products by Stage and Molecule Type, H1 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report